Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 15/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5357692 | 0.87 | FBP1 (0.76) | FBP1ADORA2AADORA1MAPK1ADORA3 | |
| SCHEMBL5359008 | 0.81 | FBP1 (0.68) | FBP1ADORA2AADORA1MAPK1ADORA3 | |
| SCHEMBL6346450 | 0.78 | FBP1 (1.00) | FBP1ADORA2AADORA1MAPK1ADORA3 | |
| SCHEMBL5732048 | 0.75 | ADORA2A (0.72) | FBP1ADORA2AADORA1MAPK1ADORA3 | |
| SCHEMBL5358021 | 0.73 | ADORA2A (0.69) | FBP1ADORA2AADORA1MAPK1ADORA3 | |
| SCHEMBL5364361 | 0.73 | ADORA2A (1.00) | FBP1ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL5357844 | 0.71 | ADORA2A (0.73) | FBP1ADORA2AADORA1MAPK1ADORA3 | |
| SCHEMBL5361216 | 0.69 | FBP1 (1.00) | FBP1ADORA2AADORA1MAPK1 | |
| SCHEMBL5376477 | 0.67 | FBP1 (0.76) | FBP1ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL5731170 | 0.66 | ADORA2A (0.57) | FBP1ADORA2AADORA1MAPK1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285543-B2 | Purine inhibitors of fructose-1,6-bisphosphatase | METABASIS THERAPEUTICS, INC. (US) | 2007-10-23 | — | — | US | disclosed |
| US-20050277619-A1 | Novel purine inhibitors of fructose-1,6-bisphosphatase | DANG QUN | 2005-12-15 | — | — | US | disclosed |
| US-6967193-B1 | Purine inhibitors of fructose-1,6-bisphosphatase | METABASIS THERAPEUTICS, INC. (US) | 2005-11-22 | — | — | US | disclosed |
| US-6284748-B1 | ANTIDIABETIC AGENT | METABASIS THERAPEUTICS, INC. | 2001-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277619-A1 | Novel purine inhibitors of fructose-1,6-bisphosphatase | FBP1, PNP, PPA1 | FBP1 1/4885ADORA2A 319/4885ADORA1 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.